The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other drug approvals ...

FDA rejects melanoma drug vusolimogene with nivolumab, citing insufficient evidence from Replimune’s phase 2 and 3 trials.

A Woburn biotechnology company is now facing a significantly larger wave of layoffs than initially disclosed — with state filings suggesting between 161 and 224 Massachusetts employees are on the ...

Replimune Group, Inc. is rated a Buy on the ability for REPL to court surprising and bold turnarounds. Learn more about REPL ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune ...

During Dr. Martin Makary’s tenure as commissioner, the FDA faced pushback over high-profile drug rejections for Replimune and ...

Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for ...

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. | As Bicara Therapeutics lines up ...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) ...

U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.

In the debate over clinical trials, a reader recounts a treatment that saved his arm from amputation.

Doctors who treat melanoma are shocked by a drug’s rejection.